Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Smoking and COPD: what really are the risks?

S. Marsh, S. Aldington, P. Shirtcliffe, M. Weatherall, R. Beasley
European Respiratory Journal 2006 28: 883-884; DOI: 10.1183/09031936.06.00074806
S. Marsh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Aldington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Shirtcliffe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Weatherall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Beasley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

Chronic obstructive pulmonary disease (COPD) is rapidly becoming a global public health crisis, with around three million people predicted to die from the disease in 2006 1, 2. There is growing awareness of the increasing global burden of COPD not only in terms of mortality, but also its prevalence, morbidity and economic costs 2. In response to these concerns, there has been a renewed research effort to understand the causes of COPD and to develop public health and pharmacological interventions that may reduce the burden.

Smoking is recognised as the most important causative factor for COPD, with an individual's susceptibility being a continuous, rather than a categorical characteristic that can interact synergistically with other risk factors. There is now evidence that most smokers develop some respiratory impairment due to COPD 3. One of the most informative recent studies addressing this issue is the Obstructive Lung Disease in North Sweden (OLIN) study 4. From this cohort study, it was reported that ∼50% of smokers eventually develop COPD, as defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2. This finding is of major clinical significance, in that it provides a scientific basis for the advice that can now be given to smokers that if they continue smoking lifelong, they have at least a one in two chance of developing COPD. Importantly, the study also provides evidence that the risk of developing COPD falls by about half with smoking cessation.

The OLIN study also allowed determination of the proportion of COPD cases that is due to smoking 4. Utilising the GOLD criteria for the diagnosis of COPD, the population attributable risk of COPD for smoking was 45% (95% confidence interval (CI) 29–58%) in the 46–77-yr age group. Utilising the British Thoracic Society criteria 5, which are considerably more stringent than the GOLD criteria for the diagnosis of COPD, the population attributable risk was 50% (95% CI 28–67%). This population attributable risk is considerably less than current dogma suggests, with a figure of 80–90% commonly quoted 6–8. A comparable population attributable risk of 44% (95% CI 38–50%) can be calculated from the third National Health and Nutrition Examination Survey (NHANES III) 9. However, this figure is qualified by the lack of post-bronchodilator lung function measurements in the NHANES III, which means that the COPD criteria employed were more inclusive of cases with asthma.

If only about half of all cases of COPD are due to smoking, what factors are responsible for the other half and what can be done to reduce their impact? It is not widely recognised that up to 20% of cases of COPD worldwide can be attributed to indoor air pollution from exposure to smoke from cooking and heating with biomass fuels in poorly ventilated dwellings 10, 11. This is likely to explain the similar prevalence of COPD in females and males in developing countries, despite markedly lower rates of smoking in females 2. Greater recognition of the role of indoor air pollution is a necessary prerequisite for the development of strategies to lessen its impact, and to reduce the occurrence of COPD.

A comparable example, which is amenable to public health and government interventions, is workplace exposure to a wide variety of dusts, chemicals and fumes. Given that up to 20% of cases of COPD may be attributed to occupational exposures 12, the potential benefit of preventive measures are apparent. As with indoor air pollution, the greatest burden of COPD due to occupational exposures is in the developing world. Other risk factors that could potentially be modified at an individual or population level are outdoor air pollution, marijuana smoking, chronic respiratory infection, diet, childhood asthma and factors associated with lung growth in utero and infancy.

We suggest that a greater understanding of the causation of chronic obstructive pulmonary disease is a research priority to provide the basis for the development of primary and secondary intervention programmes. This recommendation does not lessen the significance of tobacco smoking as the most important cause of chronic obstructive pulmonary disease, or the public health importance of measures to reduce tobacco consumption internationally. Smoking remains an important cause of global mortality, being accountable for around five million premature deaths in the world every year, including about one million due to chronic obstructive pulmonary disease 13.

    • © ERS Journals Ltd

    References

    1. ↵
      Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;365:613–620.
    2. ↵
      Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. www.goldcopd.com. Date last accessed: July 13 2006. Date last updated: 2005
    3. ↵
      Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006;367:1216–1219.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003;97:115–122.
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      British Thoracic Society. Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52: Suppl. 5 S1–S28.
      OpenUrlPubMed
    6. ↵
      Calverley PMA, MacNee W, Pride NB, Rennard SI, eds. Chronic Obstructive Pulmonary Disease. 2nd Edn. London, Arnold, 2003
    7. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121: Suppl. 5 121S–126S.
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      US Surgeon General, ed. The Health Consequences of Smoking: Chronic Obstructive Lung Disease. Publ No. 84–50205. Washington DC, USDHHS, 1984
    9. ↵
      Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function mortality in the United States: data from the first National Health and Nutrition Examination Survey follow up study. Thorax 2003;58:388–393.
      OpenUrlAbstract/FREE Full Text
    10. ↵
      World Health Report 2002. Message from the Director-General, Dr GH Brundtland. Overview. Geneva, World Health Organization, 2002; pp. ix–xx
    11. ↵
      World Health Report 2002. Message from the Director-General, Dr GH Brundtland. Quantifying selected major risks to health. Geneva, World Health Organization, 2002; pp. 68–76
    12. ↵
      Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003;22:462–469.
      OpenUrlAbstract/FREE Full Text
    13. ↵
      Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003;362:847–852.
      OpenUrlCrossRefPubMedWeb of Science
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 28 Issue 4 Table of Contents
    European Respiratory Journal: 28 (4)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Smoking and COPD: what really are the risks?
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Smoking and COPD: what really are the risks?
    S. Marsh, S. Aldington, P. Shirtcliffe, M. Weatherall, R. Beasley
    European Respiratory Journal Oct 2006, 28 (4) 883-884; DOI: 10.1183/09031936.06.00074806

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Smoking and COPD: what really are the risks?
    S. Marsh, S. Aldington, P. Shirtcliffe, M. Weatherall, R. Beasley
    European Respiratory Journal Oct 2006, 28 (4) 883-884; DOI: 10.1183/09031936.06.00074806
    Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Reply: Central apnoeas, sympathetic activation and mortality in heart failure
    • Central apnoeas, sympathetic activation and mortality in heart failure
    • Reply: Triple therapy and adverse cardiovascular events in COPD
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society